LITESPARK-011
What it tests: Belzutifan plus lenvatinib versus cabozantinib for advanced RCC after anti-PD-(L)1 therapy. Phase 3 final analysis.

Listen to Oncology Here & Now
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletterWhat it tests: Belzutifan plus lenvatinib versus cabozantinib for advanced RCC after anti-PD-(L)1 therapy. Phase 3 final analysis.
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.